SELLAS Life Sciences
94 hedge funds and large institutions have $53.1M invested in SELLAS Life Sciences in 2025 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 30 increasing their positions, 19 reducing their positions, and 5 closing their positions.
8,258% more call options, than puts
Call options by funds: $27.8M | Put options by funds: $333K
320% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 5
58% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 19
19% more funds holding
Funds holding: 79 → 94 (+15)
4.43% more ownership
Funds ownership: 26.85% → 31.28% (+4.4%)
10% less capital invested
Capital invested by funds: $58.7M → $53.1M (-$5.63M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$10.3M |
| 2 |
BlackRock
New York
|
+$1.95M |
| 3 |
EFG
Everhart Financial Group
Dublin,
Ohio
|
+$590K |
| 4 |
Renaissance Technologies
New York
|
+$520K |
| 5 |
State Street
Boston,
Massachusetts
|
+$442K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$1.45M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.12M |
| 3 |
Goldman Sachs
New York
|
-$795K |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$637K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$400K |
SLS Hedge Fund Activity: Q3 2025 in Review
94 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in SELLAS Life Sciences (SLS) for Q3 2025, worth a combined $53.1M — down 9.6% from $58.7M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new SLS positions and 5 closed out — a net gain of 16 holders — while 30 added to existing stakes and 19 trimmed.
The largest buyer was Anson Funds Management, adding an estimated $10.3M. The largest seller was Millennium Management, cutting an estimated $1.45M.
- 94 institutional investors held SELLAS Life Sciences (SLS) as of Q3 2025, up from 79 in Q2 2025.
- Funds reported $53.1M of SELLAS Life Sciences stock for Q3 2025, down 9.6% quarter-over-quarter.
- 21 funds opened new SELLAS Life Sciences positions in Q3 2025 and 5 closed out, a net change of +16 holders.
- The largest SELLAS Life Sciences buyer in Q3 2025 was Anson Funds Management, an estimated $10.3M added.
- The largest SELLAS Life Sciences seller in Q3 2025 was Millennium Management, an estimated $1.45M sold.
Based on aggregated 13F filings for Q3 2025.